Tylenol stock plummets as RFK expected to shock with autism link
FILE PHOTO: U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before a House Energy and Commerce Health Subcommittee hearing on U.S. President Donald Trump's budget request for the Department of Health and Human Services, on Capitol Hill in Washington, D.C., U.S., June 24, 2025. REUTERS/Evelyn Hockstein/File Photo

Stocks for Kenvue, $KVUE, dropped more than 15% Friday after news surfaced that Health Secretary Robert F. Kennedy, Jr. plans to announce a study indicating that Tylenol use during pregnancy could potentially cause autism.

The bizarre new claim prompted immediate backlash following his disastrous clash with lawmakers Thursday, including calls to impeach him or for him to step down from the position.

"The report is expected to suggest that potential causes of autism include low levels of folate — an important vitamin — and Tylenol taken during pregnancy, according to the WSJ," Schwab Network posted on X.

McNeil Consumer Healthcare, a division of Kenvue, makes Tylenol and other acetaminophen-based products.

Kenvue says science shows no causal link. The company disputes the claims that the medication can harm women or babies.